Q4 2024 Fennec Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fennec Pharmaceuticals Inc (FENC) reported a 40% increase in revenues over the past 12 months, demonstrating strong financial growth.
- The company successfully launched PEDMARK in major European markets, including Germany and the UK, expanding its international presence.
- PEDMARK is gaining traction in major academic centers across the US, such as UCLA and Mount Sinai, validating its clinical utility.
- Fennec Pharmaceuticals Inc (FENC) has a strong cash position with $26.6 million in cash and cash equivalents as of December 31, 2024.
- The company has made strategic hires in key management and commercial roles, strengthening its leadership team and expertise.
- The company faces challenges in increasing awareness and adoption of PEDMARK among oncologists and the AYA population.
- There is competition from compounded STS products, particularly in the pediatric market, which could impact PEDMARK's market share.
- Fennec Pharmaceuticals Inc (FENC) reported a cash burn of $0.6 million in the fourth quarter of 2024, indicating ongoing operational expenses.
- The company anticipates similar cash operating expenses in 2025, which may impact profitability despite revenue growth.
- There is uncertainty regarding the timing and outcome of regulatory and reimbursement approvals in international markets, such as Japan.
Good morning ladies and gentlemen, and welcome to Fennec Pharmaceuticals fourth quarter and full year 2024 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
Now I would like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade. Please go ahead.
Thank you, operator, and good morning everyone. We appreciate you joining us today for Fennec Pharmaceuticals fourth quarter and full year 2024 earnings conference call. During which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman.
Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
